Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the DZUVEO licensing agreement, Aguettant will have the right to commercialize DZUVEO in Europe. In 2018, AcelRx received approval for DZUVEO from the European Commission for use in medically monitored settings.
Lead Product(s): Sufentanil Citrate
Therapeutic Area: Neurology Product Name: Dzuveo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: AcelRx Pharmaceuticals
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 14, 2021